Novelty Nobility Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A
  • (Cancelled)

  • Latest Deal Amount
  • $10.8M

  • Investors
  • 31

Novelty Nobility General Information

Description

Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance. The company focuses on researching novel factors for angiogenesis to develop therapeutic antibodies for treating diseases caused by the growth of aberrant blood vessels, such as retinal diseases and solid cancerous tumors, enabling clients to access new therapeutic options in ophthalmology and oncology for their patients.

Contact Information

Formerly Known As
Comeworth Pharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 210, 686
  • Cheonggyesan-ro
  • Seongnam, Gyeonggi 13105
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Unit 210, 686
  • Cheonggyesan-ro
  • Seongnam, Gyeonggi 13105
  • South Korea

Novelty Nobility Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novelty Nobility Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 23-Aug-2025 $10.8M Cancelled Clinical Trials - Phase 1
6. Accelerator/Incubator 07-Apr-2025 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series C) 11-Nov-2024 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 15-May-2022 Completed Clinical Trials - Phase 1
3. Early Stage VC 04-Mar-2021 Completed Startup
2. Early Stage VC (Series A) 30-Jan-2020 $8.58M $9.6M Completed Startup
1. Seed Round 30-Apr-2019 $1.05M $1.05M Completed Startup
To view Novelty Nobility’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Novelty Nobility Patents

Novelty Nobility Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025261271-A1 Novel anti-cdcp1 humanized antibody and use thereof Pending 22-Apr-2024
WO-2025226017-A1 Novel anti-cdcp1 humanized antibody and use thereof Pending 22-Apr-2024
AU-2025207813-A1 Bispecific antibody specifically binding to c-kit and vegf, and use thereof Pending 12-Jan-2024
WO-2025151018-A1 Bispecific antibody specifically binding to c-kit and vegf, and use thereof Inactive 12-Jan-2024
WO-2024090927-A1 Novel anti-cdcp1 antibody and use thereof Inactive 24-Oct-2022 C07K16/2896
To view Novelty Nobility’s complete patent history, request access »

Novelty Nobility Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novelty Nobility Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
AFW Partners Venture Capital Minority
Brave New Investment PE/Buyout Minority
KDB Capital PE/Buyout Minority
LINE Investment Partners Venture Capital Minority
You’re viewing 5 of 31 investors. Get the full list »

Novelty Nobility FAQs

  • When was Novelty Nobility founded?

    Novelty Nobility was founded in 2017.

  • Where is Novelty Nobility headquartered?

    Novelty Nobility is headquartered in Seongnam, South Korea.

  • What is the size of Novelty Nobility?

    Novelty Nobility has 21 total employees.

  • What industry is Novelty Nobility in?

    Novelty Nobility’s primary industry is Drug Discovery.

  • Is Novelty Nobility a private or public company?

    Novelty Nobility is a Private company.

  • What is the current valuation of Novelty Nobility?

    The current valuation of Novelty Nobility is .

  • What is Novelty Nobility’s current revenue?

    The current revenue for Novelty Nobility is .

  • How much funding has Novelty Nobility raised over time?

    Novelty Nobility has raised $60.8M.

  • Who are Novelty Nobility’s investors?

    Johnson & Johnson Innovation - JLABS, AFW Partners, Brave New Investment, KDB Capital, and LINE Investment Partners are 5 of 31 investors who have invested in Novelty Nobility.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process